Aicuris Anti‑Infective Cures reported positive Phase 3 results for pritelivir in healing refractory herpes simplex virus lesions in immunocompromised patients and said it will prepare a U.S. NDA filing in 2026. The oral helicase‑primase inhibitor outperformed control on lesion healing endpoints in the pivotal study, positioning pritelivir as an option for patients who fail existing therapies. Aicuris plans regulatory submissions in key markets and highlighted the unmet need among immunocompromised populations where standard antivirals are less effective.